KRP 116D
Aug 21, 2020
Interstitial Cystitis: A big opportunities for emerging drugs
Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol/ Cimzia (UCB Pharma), LP-08 (Lipella Pharmaceuticals), GRT6010 (Grünenthal), ASP6294 (Astellas Pharma), and SI-...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
